American Journal of Cardiology
Volume 104, Issue 11 , Pages 1478-1483 , 1 December 2009

Usefulness of Soluble Fms-like Tyrosine Kinase-1 as a Biomarker of Acute Severe Heart Failure in Patients With Acute Myocardial Infarction

Received 20 May 2009 ,Revised 7 July 2009 ,Accepted 7 July 2009.

References 

  1. Chung NA, Makin AJ, Lip GY. Measurement of the soluble angiopoietin receptor tie-2 in patients with coronary artery disease: development and application of an immunoassay. Eur J Clin Invest. 2003;33:529–535
  2. Kodama Y, Kitta Y, Nakamura T, Takano H, Umetani K, Fujioka D, et al. Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. J Am Coll Cardiol. 2006;48:43–50
  3. Sellke FW, Wang SY, Stamler A, Lopez JJ, Li J, Li J, et al. Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. Am J Physiol Heart Circ Physiol. 1996;271:H713–H720
  4. Xu X, Li J, Simons M, Li J, Laham RJ, Sellke FW. Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thorac Cardiovasc Surg. 2001;121:735–742
  5. Li J, Brown LF, Hibberd MG, Grossman JD, Morgan JP, Simons M. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Am J Physiol Heart Circ Physiol. 1996;270:H1803–H1811
  6. Gerber HP, Condorelli F, Park J, Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes (Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia). J Biol Chem. 1997;272:23659–23667
  7. Nilsson I, Shibuya M, Wennström S. Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res. 2004;299:476–485
  8. Jayasinghe C, Simiantonaki N, Michel-Schmidt R, Kirkpatrick CJ. Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells in vitro: comparative study with HUVEC. Int J Mol Med. 2009;23:49–55
  9. Hornig C, Barleon B, Ahmad S, Vuorela P, Ahmed A, Weich HA. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Lab Invest. 2000;80:443–454
  10. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9:225–230
  11. Barleon B, Reusch P, Totzke F, Herzog C, Keck C, Martiny-Baron G, et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem. 1997;272:10382–10388
  12. Park M, Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun. 1999;264:730–734
  13. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci. 2001;114:853–865
  14. Kendall RL, Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun. 1996;226:324–328
  15. Huckle WR, Roche RI. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem. 2004;93:120–132
  16. Nielsen VG. Endogenous heparin decreases the thrombotic response to hemorrhagic shock in rabbits. J Crit Care. 2001;16:64–68
  17. Iwama H, Uemura S, Naya N, Imagawa K, Takemoto Y, Asai O, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol. 2006;47:1559–1567
  18. Takeda Y, Uemura S, Iwama H, Imagawa K, Onoue K, Somekawa S, et al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J. 2009;Epub ahead of print
  19. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–683
  20. Kita N, Mitsushita J. A possible placental factor for preeclampsia: sFlt-1. Curr Med Chem. 2008;15:711–715
  21. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649–658

PII: S0002-9149(09)01352-6

doi: 10.1016/j.amjcard.2009.07.016

American Journal of Cardiology
Volume 104, Issue 11 , Pages 1478-1483 , 1 December 2009

Article Tools

* Image Usage & Resolution